IM-101 in Myasthenia Gravis

Phase 2, randomised, double-blind trial of IM-101 in myasthenia gravis (MG) (7 arms), sponsored by ImmunAbs. Primary endpoints: [Part A] Incidence of Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Adverse Events (AEs) that led to premature discontinuation, and Adverse Events of Special Interest… at 99 days, [Part B] Incidence of Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Adverse Events (AEs) that led to premature discontinuation, and Adverse Events of Special Interest… at 169 days and 2 more. Started Feb 2026; status: recruiting.